AstraZeneca e Bristol Myers Squibb, two of the world's leading pharmaceutical companies, are reportedly evaluating a major merger that is likely to profoundly alter the balance of the sector. According to an exclusive report by Financial Times, the British group and the American competitor have reportedly started several months ago talks on a possible mergerThe operation would lead to the birth of the fourth largest pharmaceutical group in the world by market capitalization, with an overall value close to 400 billion dollarsAstraZeneca is currently valued at around $260-264 billion, while Bristol Myers Squibb has a market cap of around $133 billion.
The discussions could lead to an agreement relatively quickly, but negotiations remain uncertain. The deal could be delayed or fall through entirely.
Possible cash-for-stocks transaction
The structure of the merger has not yet been defined, but the operation could include a combination of money and actionsFor AstraZeneca, this would be one of the most important moves in its history, after a decade in which the British group performed much more favorably than Bristol Myers Squibb in the eyes of investors.
The integration would also allow AstraZeneca to further strengthen its presence in the United States, a market that already generates nearly half of the group's revenue. The American prospect has become even more concrete following the company's direct listing in New York in June. Only last week, however, the CEO Pascal Soriot had said it did not “need an acquisition” to reach its goal of $80 billion in revenue by 2030.
The oncology issue and the risks for the Antitrust
The main stumbling block industrial concerns the strong overlap between the activities of the two companies in the oncology sectorBoth groups have leading drugs used in the treatment of cancer, with possible areas of direct competition. One of the most relevant cases is that of Wonderful, developed by Bristol Myers Squibb, and Imfinzi, produced by AstraZeneca, both used to treat lung cancer. According to the FT, this overlap could actually reduce the chances of obtaining approval from antitrust authorities.
Any merger would therefore be subject to particularly stringent scrutiny, with possible demands for asset divestments or substantial changes to the structure of the operation.
The political risk of a move to the United States
In addition to the competitive issues, other relevant issues also emerge political questions. A possible choice of transfer the headquarters by AstraZeneca (now in Cambridge) in the United States It would fuel fears in the UK about the loss of one of the country's key industrial champions.
AstraZeneca is in fact the second-largest UK listed company by value and represents one of the country's most important strategic assets. A possible move overseas would attract the attention of both British and American institutions.
The mega-merger would therefore have implications that go far beyond financial aspects. At stake are control of major pharmaceutical businesses, the balance of cancer research, and the future of one of the iconic groups of British industry.
